Eye Drops for Presbyopia: Vuity, Yuvezzi, and the New Era of Reading Drop Therapy

If you have been reaching for reading glasses since your early 40s, you are not alone — presbyopia affects virtually everyone as the crystalline lens of the eye stiffens with age, gradually reducing the ability to focus up close. For decades, the only options were reading glasses, bifocals, progressive lenses, multifocal contact lenses, or surgery. That changed with the FDA approval of the first prescription eye drops specifically designed to treat presbyopia.

Here is what you need to know about this new category of treatment — including Vuity, Yuvezzi, and what is coming next.

Vuity is the first FDA-approved eye drop for presbyopia — a daily option, not a cure. It works best for patients in the early to moderate stages who want to reduce their dependence on reading glasses for specific activities.

Presbyopia is not a disease — it is a natural, age-related change in the eye's focusing system. The crystalline lens, which sits behind the iris, normally changes shape to focus at different distances (a process called accommodation). As we age, the lens gradually loses elasticity and becomes less able to change shape, reducing near focusing ability.

Most people notice presbyopia beginning around age 40–45. By the mid-50s, the near focusing ability is typically lost almost entirely. The condition is universal — it affects every person who lives long enough, regardless of whether they were previously nearsighted, farsighted, or had perfect vision.

Presbyopia drops work through a mechanism called pharmacological miosis — they cause the pupil to constrict (become smaller). A smaller pupil increases the depth of field, similar to how a camera with a smaller aperture keeps more of the scene in focus. This increased depth of field allows the eye to see near objects more clearly, even though the lens itself has not regained its flexibility.

The active ingredient in currently approved presbyopia drops is pilocarpine — a well-established medication that has been used in ophthalmology for over a century to treat glaucoma. The innovation in these new drops is the formulation: optimized concentration, pH, and delivery system to maximize near vision improvement while minimizing side effects.

Vuity (AbbVie) was the first FDA-approved eye drop specifically for presbyopia, approved in October 2021. It is a 1.25% pilocarpine solution formulated with AbbVie's proprietary pHast technology, which allows the drop to adjust to the eye's natural pH rapidly, improving comfort and onset of action.

• One drop in each eye once daily
• Applied in the morning
• Effect begins within approximately 15 minutes
• Duration of effect: approximately 6 hours for most patients

• Meaningful improvement in near and intermediate vision for many patients
• Convenient once-daily dosing
• No systemic side effects at this concentration for most patients
• Can be used with or without glasses for distance

• Effect duration (6 hours) may not cover a full workday for all patients
• Works best in patients with mild to moderate presbyopia (typically ages 40–55)
• Less effective in patients with larger pupils (lighter iris colors)
• May cause dim vision in low-light conditions due to pupil constriction
• Headache and eye redness are the most common side effects, particularly in the first few weeks

Yuvezzi (Harrow, Inc.) received FDA approval in 2024 as a second pilocarpine 1.25% drop for presbyopia. Like Vuity, it uses pilocarpine at the same concentration — but with a different formulation and delivery system.

Yuvezzi uses a different buffering and preservative system that some patients find better tolerated, particularly those with sensitive eyes or mild dry eye. The clinical efficacy data is comparable to Vuity — both produce similar improvements in near vision at the same pilocarpine concentration.

For patients who experience irritation or redness with Vuity, Yuvezzi offers a formulation alternative worth trying. The choice between the two is often driven by individual tolerance, insurance coverage, and cost.

• One drop in each eye once daily, in the morning
• Onset and duration similar to Vuity

Presbyopia drops are not for everyone. The patients who tend to benefit most are:

• Ages 40–55 with mild to moderate presbyopia — patients who still have some residual accommodation benefit most from the depth-of-field enhancement
• Patients who want occasional freedom from reading glasses — for specific activities (dinner, meetings, travel) rather than all-day use
• Contact lens wearers who find reading glasses inconvenient to manage alongside contacts
• Patients with darker irides — darker eyes tend to respond better because the pupil constricts more completely
• Patients who are not candidates for surgical correction of presbyopia

• Patients with significant dry eye (pilocarpine can worsen ocular surface symptoms in some patients)
• Patients who drive frequently at night (pupil constriction reduces low-light vision)
• Patients with a history of retinal detachment or high myopia (pilocarpine-induced miosis can rarely precipitate retinal issues in predisposed patients — discuss with your eye doctor)
• Patients on certain systemic medications that interact with cholinergic agents

This is the most important section for patients considering presbyopia drops.

What they do:

• Improve near and intermediate vision for approximately 6 hours after instillation
• Reduce dependence on reading glasses for many daily tasks
• Provide a non-surgical, reversible option for presbyopia management

What they do not do:

• Restore the full range of accommodation you had at age 30
• Replace reading glasses entirely for all patients or all tasks
• Work equally well for everyone — response varies significantly between individuals
• Provide all-day coverage for most patients (the 6-hour window is a real limitation)

The clinical trials for Vuity showed that approximately 30% of patients gained 3 or more lines of near vision improvement — a meaningful result. But that also means a significant proportion of patients had more modest improvement. A trial period is the only way to know how well they will work for you.

The approval of Vuity and Yuvezzi has opened a new category of presbyopia pharmacotherapy, and several other approaches are in development:

• Combination drops that address both the optical (pupil constriction) and accommodative components of presbyopia
• Lens-softening agents that aim to restore flexibility to the crystalline lens — a fundamentally different mechanism that could provide more complete presbyopia correction
• Longer-acting formulations that extend the duration of effect beyond 6 hours

The field is moving quickly. What is available today is the beginning of what will likely become a much more effective category of treatment over the next decade.

The best way to evaluate whether Vuity or Yuvezzi will work for you is a supervised trial — starting the drops, assessing your near vision improvement, and evaluating the side effect profile over 2–4 weeks. At Trendsetter Eyewear, Dr. Cynthia Payne can assess your candidacy, discuss realistic expectations based on your specific prescription and pupil characteristics, and monitor your response.

Presbyopia drops are not a replacement for a comprehensive approach to presbyopia management — they are one tool in a toolkit that also includes progressive lenses, multifocal contact lenses, and surgical options. The right solution depends on your lifestyle, visual demands, and how your eyes respond.

Call (702) 479-5222 or schedule an appointment at our Summerlin, Las Vegas location to discuss whether presbyopia drops are right for you.

Presbyopia eye drops are prescription medications that temporarily improve near vision by constricting the pupil, which increases depth of focus — similar to how a camera with a smaller aperture has greater depth of field. Currently available options include Vuity (pilocarpine 1.25%) and Yuvezzi (pilocarpine 1.25%). They are applied once daily and provide several hours of improved near vision.

Clinical trials show that presbyopia drops improve near vision by approximately 3 lines on a near vision chart in a meaningful percentage of patients. Results vary significantly based on pupil size, lighting conditions, and the degree of presbyopia. They work best in bright light (which already constricts the pupil) and are less effective in dim conditions. They are not a replacement for reading glasses in all situations.

The most common side effects are headache (from the pupil constriction mechanism) and dim vision in low-light conditions. Some patients experience brow ache or eye redness. Because the drops constrict the pupil, they reduce the amount of light entering the eye — which can make night driving more challenging. Patients with narrow-angle glaucoma should not use pilocarpine drops.

For some patients in some situations, yes. Presbyopia drops can reduce dependence on reading glasses for tasks like reading a menu, checking a phone, or reading labels. However, they do not provide the consistent, reliable near vision that reading glasses or progressive lenses do across all lighting conditions and distances. Most patients use them as a supplement to their optical correction rather than a complete replacement.

Presbyopia drops are typically covered under prescription drug benefits (not vision insurance) with a copay. Coverage varies by plan. The drops require a prescription from an eye doctor — Dr. Payne can evaluate whether you are a good candidate and prescribe them if appropriate during your comprehensive eye exam.